Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study()

While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower pr...

Descripción completa

Detalles Bibliográficos
Autores principales: de Renzis, Benoit, Mansat-De Mas, Veronique, Wattel, Eric, Beyne-Rauzy, Odile, Knoops, Laurent, Cabrespine, Aurélie, Azgui, Zahia, Ades, Lionel, Kiladjian, Jean-Jacques, Fenaux, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850389/
https://www.ncbi.nlm.nih.gov/pubmed/24371784
http://dx.doi.org/10.1016/j.lrr.2013.06.003
Descripción
Sumario:While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower progression to AML (p<.0011) and better overall survival (OS, p=.011). OS difference persisted after matching on age, sex, IPSS and % marrow blast (p=.031). Thus, in MDS other than RARS-T, JAK2V617F mutation may be associated with favorable outcome.

Ejemplares similares